Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial

Transplantation

Volumn 65, Issue 1, 1998, Pages 82-86

  Singh, Nina ^a,b   Gayowski, Timothy ^a   Wannstedt, Cheryl F ^a   Shakil, A Obaid ^a   Wagener, Marilyn M ^a   Fung, John J ^a   Marino, Ignazio R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FATIGUE; GRAFT REJECTION; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LEUKOPENIA; LIVER FAILURE; LIVER TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION;

ADULT; ANTIVIRAL AGENTS; FEMALE; GRAFT REJECTION; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; RECURRENCE;

EID: 0031887327     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199801150-00016     Document Type: Article

References (24)

1. Gane EJ, Portman BC, Naumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815.
2. Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology 1996; 16: 865.
3. Zhou S, Terrault NA, Ferrell L. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996; 24: 104.
4. Wright HI, Gavlier JS, VanThiel DH. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1996; 53: 121.
5. Wright TL, Combs C, Kim M, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773.
6. Singh N, Gayowski T, Wannstedt C, Marino R, Wagener MM. Interferon-alpha therapy for hepatitis C virus recurrence after liver transplantation: long-term response with maintenance therapy. Clin Transplant 1996; 10: 348.
7. Chazouilleres O, Kim M, Combs C, Ferrell L, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994.
8. Vargas HE, Wang LF, Laskus T, et al. Distribution of infecting hepatitis C virus genotypes in endstage liver disease patients at a large American transplantation center. J Infect Dis 1997; 175: 448.
9. Gayowski T, Marino IR, Singh N, et al. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome Transplantation 1997; 64: 422.
10. El-Ashmawy L, Hassanein T, Gavalier JS, VanThiel DH. Prevalence of hepatitis C virus antibody in liver transplantation population. Transplantation 1991; 114: 282.
11. Read AE, Donegan E, Lake JR, et al. Hepatitis C in patients undergoing liver transplantation. Ann Intern Med 1991; 114: 282.
12. Martin P, Monoz SJ, DiBisceglie AM, et al. Recurrence of hepatitis C virus infection after orthotopic liver transplantation. Hepatology 1991; 13: 719.
13. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431.
14. Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B related endstage liver disease. Hepatology 1994; 19: 6.
15. Rakela A, Wooten RS, Baits KP, Perkins JD, et al. Failure of interferon to prevent recurrent hepatitis B infection in hepatic allograft. Mayo Clin Proc 1989; 64: 429.
16. DiBisceglie AM. Liver transplantation for hepatitis C: the promise and the challenge. Hepatology 1995; 22: 660.
17. Kovarik J, Mayer G, Pohanka E, et al. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Transplantation 1988; 45: 402.
18. Kramer P, Ten Kate FWJ, Bijnen AB, Jeckel J, Weinar W. Recombinant leukocyte in interferon A induces steroid resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1989; 1: 989.
19. Cheeseman SH, Rubin RH, Stewart JA, et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation: effects on cytomegalovirus and herpes simplex virus infection. N Engl J Med 1979; 300: 1345.
20. Thervet E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients: a pilot study. Transplantation 1994; 58: 625.
21. Min AD, Bodenheimer HC. Does interferon precipitate rejection of liver allografts. Hepatology 1995; 22: 1333.
22. Feray C, Samuel D, Gigou M, Paradis V, et al. An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22: 1084.
23. Gadano AC, Mosnier JF, Durand F, et al. Alpha-interferon-induced rejection of a. hepatitis C virus infected liver allograft tolerated with a low dose immunosuppressive regimen. Transplantation 1995; 59: 1627.
24. Meyers JD, Flournoy N, Sanders JE, et al. Prophylactic use of human leukocyte interferon after allogenic marrow transplantation. Ann Intern Med 1987; 107: 809.